Changzhou Qianhong Biopharma CO.,LTD

Shenzhen Stock Exchange 002550.SZ

Changzhou Qianhong Biopharma CO.,LTD Shares (Diluted, Weighted) for the year ending December 31, 2023: 1,299,005,335

Changzhou Qianhong Biopharma CO.,LTD Shares (Diluted, Weighted) is 1,299,005,335 for the year ending December 31, 2023, a 1.50% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Changzhou Qianhong Biopharma CO.,LTD Shares (Diluted, Weighted) for the year ending December 31, 2022 was 1,279,800,000, a 2.40% change year over year.
Changzhou Qianhong Biopharma CO.,LTD Shares (Diluted, Weighted) for the year ending December 31, 2021 was 1,249,800,000, a 0.24% change year over year.
Changzhou Qianhong Biopharma CO.,LTD Shares (Diluted, Weighted) for the year ending December 31, 2020 was 1,246,773,100, a -0.28% change year over year.
Changzhou Qianhong Biopharma CO.,LTD Shares (Diluted, Weighted) for the year ending December 31, 2019 was 1,250,291,291, a -3.98% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

Shenzhen Stock Exchange: 002550.SZ

Changzhou Qianhong Biopharma CO.,LTD

CEO	Mr. Ke Wang
IPO Date	Feb. 18, 2011
Location	China
Headquarters	No. 90 Changjiang Middle Road
Employees	1,067
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Changzhou Qianhong Biopharma CO.,LTD engages in the research and development, production, and sale of bio-pharmaceutical products with a focus on polysaccharides and enzymes in China. The company provides various API products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; kallidinogenase kallikrein for use in the treatment of microcirculation disorders; and heparinoid. It also offers a range of preparations, such as nadroparin calcium PFS, enoxaparin sodium PFS, dalteparin sodium PFS, and asparaginase and heparin sodium injections for use as anticoagulants. In addition, the company exports its products. Changzhou Qianhong Biopharma CO.,LTD was founded in 1971 and is headquartered in Changzhou, China.

Key trends

Past 5 years